Substituted Aromatic Compounds and Pharmaceutical Uses Thereof

Abstract

The present invention relates to substituted aromatic compounds of Formula I and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds in the prevention and/or treatment of various diseases and conditions in subjects, including the prevention or treatment of (i) blood disorders, (ii) renal disorders, a nephropathies, or renal disorder complications; (iii) inflammatory-related diseases; and/or (iv) oxidative stress related disorders.

We claim: 
     
         1 . A method for preventing and/or treating an inflammatory-related disease in a patient in need thereof, comprising administering to the patient a pharmacologically effective amount of a compound represented by Formula II: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, 
         wherein: 
         n is 1; 
         Q is C 1 -C 2  alkyl optionally substituted with one R a  substituent; 
         R 1  is straight chain C 5  alkyl, C 6  alkyl, C 5 -C 6  alkenyl, or C 5 -C 6  alkynyl; 
         R 2  is H, halogen, haloalkyl, OR b , SR b , or NR c R d ; 
         R 3  is H, halogen, haloalkyl, straight chain C 1 -C 4  alkyl, OR b , SR b , or NR c R d ; 
         R 4  is H, halogen, haloalkyl, C 1 -C 4  alkyl, OR b , SR b , or NR c R d ; 
         R 5  is H or OR b ; 
         R a  is OR b , SR b , or NR c R d ; 
         R b  is H; and 
         R c  and R d  are independently chosen from: H or C 1 -C 4  alkyl. 
       
     
     
         2 . The method of  claim 1 , wherein R 1  is straight chain C 5  alkyl, C 6  alkyl, or C 5 -C 6  alkenyl; and R 2  is H, halogen, haloalkyl, or OR b . 
     
     
         3 . The method of  claim 1 , wherein R 3  is independently chosen from: H, halogen, haloalkyl, straight chain C 1 -C 4  alkyl, or OR 6 ; and R 4  is independently chosen from: H, halogen, haloalkyl, C 1 -C 4  alkyl, or OR b . 
     
     
         4 . The method of  claim 1 , wherein R a  is OR b . 
     
     
         5 . The method of  claim 1 , wherein the pharmaceutically acceptable salt is a base addition salt. 
     
     
         6 . The method of  claim 5 , wherein the base addition salt is a metal counterion. 
     
     
         7 . The method of  claim 6 , wherein the metal counterion is sodium, magnesium, calcium, potassium or lithium. 
     
     
         8 . The method of  claim 7 , wherein the metal counterion is sodium. 
     
     
         9 . The method of  claim 1 , wherein the compound is selected from the group consisting of: 
       
         
           
           
               
               
           
         
         and other pharmaceutically acceptable salts thereof and the acid form thereof. 
       
     
     
         10 . The method of  claim 9 , wherein the compound is: 
       
         
           
           
               
               
           
         
       
     
     
         11 . The method of  claim 1 , wherein the inflammatory-related disease is an immune mediated inflammatory disease or an autoimmune disease. 
     
     
         12 . The method of  claim 1 , wherein the inflammatory-related disease is an autoimmune disease. 
     
     
         13 . The method of  claim 1 , wherein the inflammatory-related disease is selected from the group consisting of arthritis, systemic lupus erythematosus (SLE), ITP, glomerulonephritis, vasculitis, psoriatic arthritis, psoriasis, Crohn's disease, inflammatory bowel disease, ankylosing spondylitis, Sjögren's syndrome, Still's disease, uveitis, scleroderma, myositis, Reiter's syndrome, and Wegener's syndrome. 
     
     
         14 . A method for treating an inflammatory-related disease in a patient in need thereof, comprising administering to the patient a pharmacologically effective amount of a compound selected from 
       
         
           
           
               
               
           
         
       
       and other pharmaceutically acceptable salts thereof and the acid form thereof. 
     
     
         15 . The method of  claim 14 , wherein the pharmaceutically acceptable salt is a base addition salt. 
     
     
         16 . The method of  claim 15 , wherein the base addition salt is a metal counterion. 
     
     
         17 . The method of  claim 16 , wherein the metal counterion is sodium, magnesium, calcium, potassium or lithium. 
     
     
         18 . The method of  claim 17 , wherein the metal counterion is sodium.